INR 2040.15
(2.62%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 816.16 Million INR | -28.86% |
2022 | 1.14 Billion INR | 1.5% |
2021 | 1.13 Billion INR | 48.09% |
2020 | 763.31 Million INR | 7.97% |
2019 | 706.97 Million INR | 20.56% |
2018 | 586.38 Million INR | 21.98% |
2017 | 480.72 Million INR | 34.54% |
2016 | 357.31 Million INR | -1.4% |
2015 | 362.39 Million INR | 4.67% |
2014 | 346.21 Million INR | 17.02% |
2013 | 295.87 Million INR | 38.35% |
2012 | 213.86 Million INR | 42.15% |
2011 | 150.45 Million INR | 4.92% |
2010 | 143.39 Million INR | 2637.32% |
2009 | 5.23 Million INR | -10.34% |
2008 | 5.84 Million INR | -91.0% |
2007 | 64.91 Million INR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 223.14 Million INR | -9.07% |
2023 Q4 | 245.38 Million INR | -31.4% |
2023 FY | 816.16 Million INR | -28.86% |
2023 Q1 | 301.1 Million INR | -0.38% |
2023 Q2 | 328.95 Million INR | 9.25% |
2023 Q3 | 357.72 Million INR | 8.75% |
2022 Q1 | 314.67 Million INR | 9.86% |
2022 Q3 | 265.6 Million INR | -5.63% |
2022 Q2 | 281.45 Million INR | -10.56% |
2022 Q4 | 302.26 Million INR | 13.8% |
2022 FY | 1.14 Billion INR | 1.5% |
2021 Q3 | 291.17 Million INR | 2.98% |
2021 Q4 | 286.43 Million INR | -1.63% |
2021 Q1 | 222.18 Million INR | 17.58% |
2021 FY | 1.13 Billion INR | 48.09% |
2021 Q2 | 282.73 Million INR | 27.26% |
2020 FY | 763.31 Million INR | 7.97% |
2020 Q2 | 200.9 Million INR | 42.32% |
2020 Q4 | 188.95 Million INR | -18.61% |
2020 Q3 | 232.17 Million INR | 15.57% |
2020 Q1 | 141.16 Million INR | -12.15% |
2019 FY | 706.97 Million INR | 20.56% |
2019 Q4 | 160.68 Million INR | -12.54% |
2019 Q1 | 178.1 Million INR | 59.25% |
2019 Q3 | 183.72 Million INR | 0.35% |
2019 Q2 | 183.08 Million INR | 2.79% |
2018 Q4 | 111.84 Million INR | -27.56% |
2018 FY | 586.38 Million INR | 21.98% |
2018 Q2 | 165.66 Million INR | -1.76% |
2018 Q1 | 168.63 Million INR | 22.24% |
2018 Q3 | 154.4 Million INR | -6.8% |
2017 Q2 | 123.93 Million INR | 8.67% |
2017 Q4 | 137.95 Million INR | 10.32% |
2017 FY | 480.72 Million INR | 34.54% |
2017 Q3 | 125.05 Million INR | 0.9% |
2017 Q1 | 114.04 Million INR | 15.35% |
2016 Q1 | 94.4 Million INR | -0.63% |
2016 FY | 357.31 Million INR | -1.4% |
2016 Q3 | 86.92 Million INR | 9.59% |
2016 Q4 | 98.86 Million INR | 13.74% |
2016 Q2 | 79.31 Million INR | -15.98% |
2015 Q1 | 89.76 Million INR | -3.05% |
2015 Q3 | 87.29 Million INR | -3.84% |
2015 Q4 | 95 Million INR | 8.83% |
2015 FY | 362.39 Million INR | 4.67% |
2015 Q2 | 90.78 Million INR | 1.13% |
2014 Q2 | 83.04 Million INR | 2.73% |
2014 Q4 | 92.59 Million INR | 4.49% |
2014 FY | 346.21 Million INR | 17.02% |
2014 Q1 | 80.84 Million INR | 8.22% |
2014 Q3 | 88.61 Million INR | 6.7% |
2013 Q2 | 73.74 Million INR | -1.57% |
2013 Q4 | 74.7 Million INR | -4.78% |
2013 FY | 295.87 Million INR | 38.35% |
2013 Q3 | 78.45 Million INR | 6.39% |
2013 Q1 | 74.92 Million INR | 22.3% |
2012 Q1 | 43.76 Million INR | 15.76% |
2012 FY | 213.86 Million INR | 42.15% |
2012 Q4 | 61.26 Million INR | 4.9% |
2012 Q3 | 58.4 Million INR | 15.57% |
2012 Q2 | 50.53 Million INR | 15.47% |
2011 Q3 | 41.15 Million INR | 0.0% |
2011 Q4 | 37.8 Million INR | -8.12% |
2011 FY | 150.45 Million INR | 4.92% |
2010 FY | 143.39 Million INR | 2637.32% |
2009 FY | 5.23 Million INR | -10.34% |
2008 Q4 | 27.9 Million INR | 0.0% |
2008 FY | 5.84 Million INR | -91.0% |
2007 FY | 64.91 Million INR | 0.0% |
2007 Q4 | 14.08 Million INR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Abbott India Limited | 5.98 Billion INR | 86.366% |
Cipla Limited | 59.21 Billion INR | 98.622% |
Gland Pharma Limited | 3.86 Billion INR | 78.865% |
GlaxoSmithKline Pharmaceuticals Limited | 4.35 Billion INR | 81.269% |
Kopran Limited | 859.54 Million INR | 5.047% |
Marksans Pharma Limited | 3.28 Billion INR | 75.188% |
Pfizer Limited | 4.33 Billion INR | 81.182% |
Sanofi India Limited | 3.69 Billion INR | 77.9% |
SMS Pharmaceuticals Limited | 370.89 Million INR | -120.054% |